Abstract
Different market share values for TBE vaccines in Austria are reported during the period 2018–2020. However, both data likely cover a significant under-estimation of doses distributed. Thus, for epidemiological evaluations, market share should be used with prudence and only reported when solid whole-market market share can be validated and referenced.